BioXcel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

BioXcel Therapeutics

12/08/2025 14:32

BioXcel Therapeutics Inc BTAI.OQ reported a quarterly adjusted loss of $2.45​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.36.  The mean expectation of five analysts for the quarter was for a loss of $1.86 per share. Wall Street expected results to range from $-2.74 to $-1.13 per share.

Revenue fell 89.1% to $120.00 thousand from a year ago; analysts expected $250.00 thousand.

BioXcel Therapeutics Inc's reported EPS for the quarter was a loss of $2.45​.

The company reported a quarterly loss of $19.19 million.

BioXcel Therapeutics Inc shares had risen by 253.6% this quarter and gained 7.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 9.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $6.00, about 6.7% below its last closing price of $6.40

This summary was machine generated from LSEG data August 12 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.86
-2.45
Missed
Mar. 31 2025
-6.66
-1.50
Beat
Dec. 31 2024
-6.42
-3.57
Beat
Sep. 30 2024
-8.67
-5.12
Beat